Luxturna (Voretigene Neparvovec): Uses, Dosage & Side Effects
The first FDA- and EMA-approved gene therapy for inherited retinal dystrophy caused by biallelic RPE65 mutations, restoring functional vision through a single subretinal injection per eye.
Luxturna (voretigene neparvovec) is a groundbreaking gene therapy approved for the treatment of inherited retinal dystrophy caused by confirmed biallelic mutations in the RPE65 gene. It is the first directly administered gene therapy approved by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a genetic disease. Luxturna works by delivering a functional copy of the RPE65 gene to retinal cells, enabling the production of a protein essential for the visual cycle and restoring the ability to detect light.
Quick Facts: Luxturna
Key Takeaways
- Luxturna is the first gene therapy approved for an inherited retinal disease, targeting vision loss caused by biallelic RPE65 gene mutations that would otherwise lead to progressive blindness.
- Treatment involves a one-time subretinal injection in each eye, performed under general anesthesia by a retinal surgeon experienced in macular surgery, with at least 6 days between eyes.
- Clinical trials demonstrated significant improvements in functional vision, including the ability to navigate obstacle courses at progressively lower light levels, with benefits sustained for at least 4 years.
- Immunosuppressive therapy with corticosteroids is required before and after each procedure to prevent the immune system from rejecting the viral vector and its gene product.
- Common side effects are primarily related to the surgical procedure and include conjunctival redness, cataracts, increased eye pressure, and transient visual disturbances. Air travel must be avoided until the intraocular air bubble is fully absorbed.
What Is Luxturna and What Is It Used For?
Luxturna (voretigene neparvovec) is a gene replacement therapy that treats inherited retinal dystrophy caused by mutations in the RPE65 gene. By delivering a working copy of the gene directly into retinal cells, Luxturna enables the production of the RPE65 protein needed for the visual cycle, improving the ability to see in low light and restoring functional vision.
Luxturna is approved for use in both adults and children with vision loss due to inherited retinal dystrophy caused by confirmed biallelic (both copies) mutations in the RPE65 gene. These mutations prevent the body from producing the RPE65 protein, a critical enzyme in the retinal pigment epithelium that converts all-trans-retinyl esters into 11-cis-retinol. Without this protein, the visual cycle is disrupted, and photoreceptor cells cannot properly detect light, leading to progressive vision loss and ultimately blindness.
The RPE65 gene is located on chromosome 1 and encodes a 65-kilodalton protein expressed exclusively in the retinal pigment epithelium (RPE). Mutations in this gene cause a spectrum of inherited retinal dystrophies, including Leber congenital amaurosis type 2 (LCA2) and early-onset severe retinal dystrophy (EOSRD). These conditions typically present in early childhood with night blindness and progressive loss of peripheral vision, eventually leading to severe visual impairment or complete blindness. It is estimated that RPE65 mutations account for approximately 2% of all inherited retinal dystrophies, affecting roughly 1,000 to 2,000 individuals in the United States and 2,000 to 3,000 in Europe.
The active substance in Luxturna, voretigene neparvovec, is a genetically modified adeno-associated virus serotype 2 (AAV2) that carries a functional copy of the human RPE65 gene. AAV2 was chosen as the delivery vector because it naturally infects retinal cells, does not cause disease in humans, and does not integrate into the host cell genome in a way that poses a significant risk of insertional mutagenesis. After subretinal injection, the AAV2 vector enters retinal pigment epithelial cells and delivers the RPE65 gene to the cell nucleus, where it remains as an episome (a circular DNA structure outside the chromosomes) and directs the production of functional RPE65 protein.
Luxturna was developed by Spark Therapeutics (now part of Roche) and received its first regulatory approval from the FDA in December 2017, making it the first directly administered gene therapy approved in the United States for a genetic disease. The EMA granted marketing authorization in November 2018. It is marketed by Novartis in Europe. The approval was based on pivotal Phase 3 clinical trial data demonstrating that treated patients experienced significant and clinically meaningful improvements in their ability to navigate in low-light environments, as measured by the multi-luminance mobility test (MLMT).
You can only receive Luxturna if genetic testing confirms that your vision loss is caused by mutations in both copies of the RPE65 gene. Your ophthalmologist will also assess whether you have sufficient viable retinal cells to benefit from treatment, as the gene therapy requires functional retinal pigment epithelial cells to produce the RPE65 protein.
What Should You Know Before Receiving Luxturna?
Before receiving Luxturna, your doctor will perform a comprehensive evaluation including genetic testing, retinal assessment, and review of your medical history. Treatment cannot proceed if you have an active eye infection, eye inflammation, or any active infection elsewhere in the body.
Contraindications
Luxturna must not be administered if you are allergic to voretigene neparvovec or any of the excipients in the formulation. Treatment is also contraindicated in patients with an active ocular (eye) infection or active ocular inflammation, as these conditions could be exacerbated by the surgical procedure and the introduction of the viral vector. If you have any signs of infection or inflammation, your doctor will postpone the procedure until the condition has fully resolved.
Additionally, patients with any active systemic infection should not receive Luxturna, as the immunosuppressive therapy required around the procedure (corticosteroids) may worsen the infection. Your treating physician will carefully evaluate your overall health status before scheduling the treatment.
Warnings and Precautions
Several important warnings and precautions apply to Luxturna treatment. Before the procedure, inform your doctor if you have any signs of eye infection or inflammation, such as red eyes, light sensitivity, eye swelling, or eye pain. Report any active infection of any kind, as the immunosuppressive medication given around treatment may reduce your body's ability to fight infections.
After the procedure, seek immediate medical attention if you experience any of the following symptoms in either or both eyes: redness, pain, light sensitivity, seeing flashes of light or floaters (spots and specks in your visual field), worsening or blurred vision. These could indicate serious complications such as endophthalmitis (severe intraocular infection) or retinal detachment, which require urgent treatment.
You must avoid air travel and travel to high altitudes until your doctor advises it is safe. During the procedure, an air bubble is placed in the eye, which is gradually absorbed by the body. Before the bubble is fully absorbed, changes in altitude or cabin pressure during flights can cause the bubble to expand, potentially causing serious eye damage including permanent vision loss. Your surgeon will monitor the air bubble and advise when flying is safe.
After treatment, you should also avoid swimming due to the increased risk of eye infection, and refrain from strenuous physical activity due to the increased risk of eye injury. Discuss with your doctor when it is safe to resume these activities. Transient visual disturbances such as light sensitivity and blurred vision may occur and should be reported to your treating physician, who can help manage any discomfort.
The active substance in Luxturna may be temporarily shed in your tears. You and your caregivers should place any used dressings and waste materials that come into contact with tear fluid or nasal secretions into sealed bags before disposing of them as household waste. Follow these precautions for 14 days after treatment.
After receiving Luxturna, you may not be eligible to donate blood, organs, tissues, or cells for transplantation. This is because the treatment involves a genetically modified organism that could potentially be transferred through these donations.
Children and Adolescents
Luxturna has not been studied in children under 4 years of age, and data in younger pediatric populations are limited. The safety and efficacy profile in children aged 4 years and older is generally consistent with that observed in adults in clinical trials. No dose adjustment is necessary for pediatric patients aged 4 years and above. The decision to treat children should be made by a specialist experienced in managing inherited retinal dystrophies, taking into account the child's ability to tolerate the surgical procedure and anesthesia.
Pregnancy and Breastfeeding
The effects of Luxturna on pregnancy and the unborn child are unknown. As a precautionary measure, Luxturna should not be administered during pregnancy. If you are pregnant, think you might be pregnant, or are planning to become pregnant, discuss the risks and benefits with your doctor before treatment.
It is not known whether Luxturna or its components pass into breast milk. If you are breastfeeding or plan to breastfeed, talk to your doctor. Your physician will help you weigh the benefits of breastfeeding against the benefits of Luxturna treatment to decide the best course of action.
Driving and Operating Machinery
You may experience transient visual disturbances after receiving Luxturna. Do not drive or operate heavy machinery until your vision has recovered sufficiently. Your ophthalmologist will advise you when it is safe to resume these activities, typically after the postoperative recovery period and once any visual disturbances have resolved.
How Does Luxturna Interact with Other Medicines?
No formal drug interaction studies have been conducted with Luxturna. Because it is a gene therapy delivered directly to retinal cells via subretinal injection, systemic drug interactions are not expected. However, the immunosuppressive corticosteroid regimen required around the procedure may interact with other medications.
Unlike conventional small-molecule drugs or biologics that circulate systemically, Luxturna is administered directly into the subretinal space, and the AAV2 vector primarily transduces local retinal pigment epithelial cells. The systemic exposure to voretigene neparvovec is minimal, making traditional pharmacokinetic drug interactions extremely unlikely. However, patients should inform their treating physician about all medications they are currently taking, have recently taken, or plan to take, as this information is relevant to overall perioperative management.
The main pharmacological interaction consideration relates to the perioperative immunosuppressive regimen. Patients receive systemic prednisone (or equivalent corticosteroid) starting 3 days before each eye procedure and continuing for approximately 18 days afterward. Corticosteroids interact with a range of other medications, and these interactions should be evaluated by the treating physician.
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| NSAIDs (ibuprofen, naproxen) | Increased risk of gastrointestinal bleeding and ulceration when combined with corticosteroids | Avoid concurrent use or use gastroprotective agents |
| Oral anticoagulants (warfarin) | Corticosteroids may alter anticoagulant effect; increased bleeding risk during surgery | Close INR monitoring; coordinate with surgeon |
| Antidiabetic medications | Corticosteroids can raise blood glucose levels, reducing effectiveness of diabetes medications | Increased blood glucose monitoring; dose adjustments may be needed |
| Live vaccines | Immunosuppressive doses of corticosteroids may reduce immune response and increase risk of vaccine-related infections | Avoid live vaccines during immunosuppressive period |
| CYP3A4 inhibitors (ketoconazole, ritonavir) | May increase systemic corticosteroid exposure by inhibiting prednisone metabolism | Monitor for corticosteroid side effects; dose adjustment may be considered |
The corticosteroid regimen is essential to prevent an immune response against the AAV2 vector and the newly produced RPE65 protein. Do not stop taking your corticosteroids without consulting your doctor, even if you experience side effects. Your physician will taper the dose according to the prescribed schedule.
What Is the Correct Dosage of Luxturna?
Each eye receives a single dose of 1.5 × 1011 vector genomes of voretigene neparvovec in a total injection volume of 0.3 mL, administered by subretinal injection after vitrectomy. The second eye is treated at least 6 days after the first.
Luxturna is a one-time treatment for each eye. The treatment must be initiated and administered by a retinal surgeon with experience in macular (vitreoretinal) surgery, in an operating room under controlled aseptic conditions. Each eye receives a single dose containing 1.5 × 1011 vector genomes (vg) of voretigene neparvovec in a total injectable volume of 0.3 mL. The concentrate vial contains 5 × 1012 vg/mL and must be diluted 1:10 before administration.
The Surgical Procedure
The treatment is performed under general anesthesia. The surgeon first performs a standard pars plana vitrectomy (removal of the vitreous gel from the center of the eye) and then carefully injects the diluted Luxturna solution into the subretinal space (beneath the retina) using a specialized subretinal injection cannula. The recommended injection site is along the superior vascular arcade, at least 2 mm from the center of the fovea to avoid damage to central vision. After injection, the vitreous cavity is filled with air, and the patient must maintain a supine (face-up) head position for 24 hours after surgery.
Adults and Children (4 years and older)
Dose: 1.5 × 1011 vector genomes per eye in 0.3 mL diluted solution
Route: Subretinal injection after vitrectomy
Frequency: One-time treatment per eye
Interval between eyes: Minimum 6 days
No dose adjustment is required based on age, weight, or renal/hepatic function.
Immunosuppressive Regimen
Patients must receive immunomodulatory therapy with systemic corticosteroids before and after each eye procedure to prevent immune-mediated rejection of the viral vector. Before starting immunosuppression, patients should be examined for any signs of active infection, and treatment should be deferred if infection is present.
| Timing | Duration | Prednisone Dose |
|---|---|---|
| Preoperative | 3 days before procedure | 1 mg/kg/day (max 40 mg/day) |
| Postoperative (Days 0–4) | 4 days (including day of procedure) | 1 mg/kg/day (max 40 mg/day) |
| Taper phase 1 | 5 days | 0.5 mg/kg/day (max 20 mg/day) |
| Taper phase 2 | 5 days (every other day dosing) | 0.5 mg/kg every other day (max 20 mg/day) |
The immunosuppressive regimen for the second eye follows the same schedule, beginning 3 days before the second procedure. The regimen for the second eye replaces the completion of the first eye's regimen. It is critical that patients do not stop taking corticosteroids without medical advice, as premature discontinuation could trigger an immune response that reduces the effectiveness of the gene therapy.
Elderly Patients
The safety and efficacy of Luxturna in patients aged 65 years and older have not been established. Clinical trial data in this population are limited. However, no dose adjustment is considered necessary for elderly patients based on the mechanism of action and the local route of administration.
Overdose
Since Luxturna is administered by a physician in a controlled surgical environment, overdose is extremely unlikely. Each vial is a single-dose preparation for one eye only. If an overdose were to occur, the physician would treat any symptoms as needed. Any excess medication remaining after injection must be discarded and must not be stored for future use.
What Are the Side Effects of Luxturna?
The most common side effects of Luxturna are related to the surgical procedure (vitrectomy and subretinal injection) and include conjunctival redness (hyperemia), cataracts, increased intraocular pressure, and retinal tears. The gene therapy itself may cause subretinal deposits and, in rare cases, retinal or choroidal atrophy.
Like all medicines, Luxturna can cause side effects, although not everybody experiences them. Most side effects observed in clinical trials were related to the vitrectomy procedure and subretinal injection rather than to the gene therapy product itself. The majority of procedure-related side effects were mild to moderate in severity and resolved without lasting complications. Below is a comprehensive overview of reported side effects organized by frequency.
Side Effects from the Gene Therapy
Common
May affect up to 1 in 10 people
- Subretinal deposits (material deposited beneath the retina)
Frequency Not Known
Cannot be estimated from available data
- Retinal atrophy (thinning of the retina)
- Choroidal atrophy (thinning of the choroid, the vascular layer beneath the retina)
Side Effects from the Surgical Procedure
Very Common
May affect more than 1 in 10 people
- Conjunctival hyperemia (red eye)
- Cataract (clouding of the lens)
- Increased intraocular pressure
Common
May affect up to 1 in 10 people
- Retinal tear (damage to the retina)
- Eye pain
- Eye swelling (macular edema)
- Retinal detachment
- Vitreous hemorrhage (bleeding in the back of the eye)
- Eye discomfort or increased eye pain
- Macular hole (blurred central vision due to a hole in the center of the retina)
- Dellen (thinning of the eye surface)
- Eye irritation
- Eye inflammation (uveitis)
- Foreign body sensation in the eye
- Abnormalities in the back of the eye
- Nausea, vomiting, abdominal pain, lip pain
- Changes in heart electrical activity (ECG changes)
- Headache, dizziness
- Skin rash, facial swelling
- Anxiety
- Complications from intubation (placement of breathing tube)
- Wound dehiscence (surgical wound opening)
Frequency Not Known
Cannot be estimated from available data
- Vitreous opacities (clouding of the gel-like substance in the eye)
- Retinal and choroidal atrophy
Bleeding, swelling, and an increased risk of infection may occur as a result of damage to eye tissues during surgery. Vision is typically reduced in the days immediately following the procedure and usually recovers on its own. Inform your doctor if your vision does not return after the initial recovery period. Transient visual disturbances such as light sensitivity and blurred vision are common in the early postoperative period and generally resolve within days to weeks.
Contact your doctor or seek emergency care immediately if you experience sudden vision loss, severe eye pain, sudden onset of floaters or flashes of light, or any signs of eye infection (increasing redness, discharge, or swelling) after the procedure. These symptoms could indicate retinal detachment or endophthalmitis, both of which require urgent treatment.
How Should Luxturna Be Stored?
Luxturna must be stored and transported frozen at ≤ −65°C (−85°F). It is prepared and handled exclusively by healthcare professionals in the hospital or treatment center. Patients do not need to store this medication at home.
Luxturna is stored by healthcare professionals at the treatment facility. The concentrate and diluent must be stored and transported in a frozen state at temperatures of −65°C or below. Once thawed, the product must not be refrozen and should remain at room temperature (below 25°C / 77°F). The diluted solution must be prepared under aseptic conditions within 4 hours before the start of administration.
Once diluted, Luxturna should be used promptly. Any unused product must be discarded after the injection procedure. The backup syringe must not be retained for future use. The product should not be used after the expiration date stated on the label and outer carton (after EXP). As a patient, you will not be responsible for the storage of Luxturna, as it is entirely managed by the clinical team at the surgical center.
What Does Luxturna Contain?
Each dose of Luxturna contains voretigene neparvovec, a genetically modified AAV2 virus carrying a functional human RPE65 gene. The concentrate contains 5 × 1012 vector genomes per mL, diluted to deliver 1.5 × 1011 vector genomes in the final 0.3 mL injection volume.
The active substance is voretigene neparvovec. Each milliliter of concentrate contains 5 × 1012 vector genomes (vg). The concentrate (0.5 mL extractable volume in a 2 mL single-dose vial) is diluted 1:10 before administration. Each dose of the diluted solution contains 1.5 × 1011 vector genomes of voretigene neparvovec in an injectable volume of 0.3 mL.
The other ingredients (excipients) in both the concentrate and diluent are:
- Sodium chloride (contributes less than 1 mmol / 23 mg sodium per dose, essentially “sodium-free”)
- Sodium dihydrogen phosphate monohydrate (for pH adjustment)
- Disodium hydrogen phosphate dihydrate (for pH adjustment)
- Poloxamer 188
- Water for injections
This medicine contains genetically modified organisms (GMOs). Each foil protective pouch contains a carton with 1 vial of 0.5 mL concentrate and 2 vials of diluent (1.7 mL each). The concentrate appears as a clear, colorless solution in a clear plastic vial. The diluent is also a clear, colorless liquid supplied in clear plastic vials.
Luxturna is manufactured by Novartis Pharma GmbH (Nuremberg, Germany) and the marketing authorization holder is Novartis Europharm Limited (Dublin, Ireland). In the United States, it is marketed by Spark Therapeutics, Inc. (a Roche company).
Frequently Asked Questions About Luxturna
Luxturna (voretigene neparvovec) is a gene therapy that treats inherited retinal dystrophy caused by mutations in both copies of the RPE65 gene. It works by using a harmless modified virus (AAV2) to deliver a functional copy of the RPE65 gene directly into the retinal pigment epithelial cells in the back of the eye. Once inside these cells, the gene produces the RPE65 protein, which is essential for converting light signals into electrical signals that the brain can interpret as vision. By restoring production of this missing protein, Luxturna improves the ability to see, particularly in low-light conditions.
Luxturna is approved for adults and children (aged 4 years and older in the EU) who have vision loss caused by inherited retinal dystrophy due to confirmed biallelic RPE65 gene mutations. This means both copies of the RPE65 gene must carry mutations. Genetic testing is mandatory to confirm eligibility. Additionally, patients must have sufficient viable retinal cells, as determined by clinical examination, to benefit from the treatment. Patients with active eye infections or inflammation must wait until these conditions resolve before receiving treatment.
Luxturna is designed as a one-time treatment for each eye. The gene therapy is delivered via a single subretinal injection per eye during a surgical procedure. Each eye is treated separately, with a minimum of 6 days between procedures. Long-term follow-up data from clinical trials have shown that the improvements in functional vision are sustained for at least 4 years after treatment. The delivered gene is expected to continue producing the RPE65 protein for an extended period, though lifelong monitoring is recommended. Re-treatment of the same eye has not been studied.
After the procedure, you will remain in the recovery area for observation for several hours. You must maintain a supine (face-up) head position for 24 hours after surgery. Vision in the treated eye will typically be reduced for several days to weeks after the procedure and gradually improves. You will need to continue taking immunosuppressive corticosteroids as prescribed. You must avoid air travel until the intraocular air bubble is fully absorbed, avoid swimming to reduce infection risk, and refrain from strenuous physical activity. Regular follow-up appointments with your ophthalmologist are essential to monitor healing and visual improvement.
Luxturna has a list price of approximately $425,000 per eye ($850,000 for both eyes) in the United States, making it one of the most expensive therapies available. In Europe, pricing is negotiated individually with each country's health authority. Many public health insurance systems and private insurers provide coverage for Luxturna, often through outcomes-based contracts where payment depends on treatment success. Patient assistance programs may also be available. Discuss with your treatment center and insurance provider to understand your coverage options and any out-of-pocket costs.
No, you must avoid air travel and travel to high altitudes after receiving Luxturna until your ophthalmologist confirms it is safe. During the vitrectomy procedure, an air bubble is placed inside the eye to help the retina heal. This bubble is gradually absorbed by the body over days to weeks. Flying or traveling to high altitudes before the bubble is fully absorbed can cause it to expand due to pressure changes, which can lead to a dangerous increase in intraocular pressure and potentially permanent vision loss. Your doctor will monitor the bubble's absorption at follow-up appointments and let you know when air travel is safe.
References
- Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet. 2017;390(10097):849-860. doi:10.1016/S0140-6736(17)31868-8
- Maguire AM, Russell S, Chung DC, et al. Durability of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease: Phase 3 results at 3 and 4 years. Ophthalmology. 2021;128(10):1460-1468. doi:10.1016/j.ophtha.2021.03.031
- European Medicines Agency. Luxturna (voretigene neparvovec): EPAR - Product Information. EMA/710726/2018. Last updated 2025.
- U.S. Food and Drug Administration. LUXTURNA (voretigene neparvovec-rzyl) Prescribing Information. Spark Therapeutics, Inc. Revised 2023.
- Garafalo AV, Cideciyan AV, Heon E, et al. Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives. Progress in Retinal and Eye Research. 2020;77:100827. doi:10.1016/j.preteyeres.2019.100827
- Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Human Gene Therapy. 2008;19(10):979-990. doi:10.1089/hum.2008.107
- Bainbridge JWB, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. New England Journal of Medicine. 2015;372(20):1887-1897. doi:10.1056/NEJMoa1414221
- Pennesi ME, Weleber RG, Yang P, et al. Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy. Human Gene Therapy. 2022;33(17-18):982-992. doi:10.1089/hum.2022.105
- World Health Organization. Blindness and vision impairment: priority eye diseases. WHO Fact Sheet. 2023.
- National Institute for Health and Care Excellence (NICE). Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations. Technology appraisal guidance [TA611]. Published September 2019.
Editorial Team
This article has been written and reviewed by healthcare professionals to ensure medical accuracy and reliability. Our editorial process follows international standards for evidence-based medical information.
Content developed by iMedic's medical writing team with expertise in ophthalmology, genetics, and gene therapy. All information is based on approved product information (EMA SmPC and FDA label) and peer-reviewed clinical trial data.
Reviewed by iMedic Medical Review Board, an independent panel of physicians and pharmacists with specialist knowledge in clinical pharmacology and inherited retinal diseases.
This article is based on Evidence Level 1A sources including randomized controlled trials (Phase 3), regulatory agency assessments (EMA EPAR, FDA review), systematic reviews, and international clinical guidelines (NICE TA611).
iMedic receives no funding from pharmaceutical companies. All content is produced independently and is free from commercial influence. We have no conflicts of interest to declare regarding this medicine.